Annovis Bio, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2026, two of our directors or "officers," as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, terminated a Rule 10b5-1 trading plan or arrangement or anon-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K. None of our directors or "officers," as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted a Rule 10b5-1 trading plan or arrangement or anon-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K.
| | | | | | |
|---|---|---|---|---|---|
| Name and Title | Action | Date | Plan | Aggregate Number of securities to be sold | Plan Expiration Date |
| Maria Maccecchini, CEO & Director | Terminated | 17-Dec-24 | Rule 10b5-1 | 270,000 | 16-Sep-26 |
| Mark White, Director | Terminated | 17-Dec-24 | Rule 10b5-1 | 51,426 | 30-Sep-26 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.